Answers are grounded in this paper and cite their sources.
Cystic fibrosis transmembrane conductance regulator modulators (CFTRm) have revolutionized the care of patients with cystic fibrosis. There are several clinical justifications for CFTRm therapeutic drug monitoring. To facilitate the implementation of this service, we developed a liquid chromatography–tandem mass spectrometry (LC-MS/MS) assay for quantifying CFTRm concentrations in human plasma. A high-throughput LC-MS/MS assay was developed for the simultaneous quantification of current and emerging CFTRm, including deutivacaftor, vanzacaftor, ivacaftor, lumacaftor, tezacaftor and elexacaftor, along with major metabolites (hydroxymethyl-ivacaftor, ivacaftor-carboxylate, tezacaftor-M1, and elexacaftor-M23). Sample preparation involved protein precipitation using 5 μL plasma, ensuring efficiency and minimal sample requirement. Chromatographic separation was achieved using a C18 column. Detection was performed via positive electrospray ionization in multiple-reaction-monitoring mode, with stable isotope-labeled internal standards. The instrument runtime was 3.5 minutes, supporting rapid analysis for a high-throughput laboratory. The assay demonstrated a linear range of 0.01 to 10 mg/L for all analytes. Method validation demonstrated high accuracy and precision. Stability studies indicated that all analytes remained stable in plasma under a range of tested conditions. This validated LC–MS/MS method is robust, sensitive, and suitable for routine clinical application. The short runtime and minimal sample volume support its use in high-throughput settings. Cystic fibrosis transmembrane conductance regulator modulators (CFTRm) are new medicines that have transformed the treatment of cystic fibrosis. However, people can respond differently to these medicines, and it is not yet known whether measuring the amount of these medicines in a patient’s blood sample could help explain these differences. We developed a test that can measure all currently available CFTRm medicines in a single blood sample. This test requires only a small amount of blood and provides accurate and precise measurements. In the future, this method could become routine practice to help personalize treatment for individual patients.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: